Detalles de la búsqueda
1.
Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
J Asthma
; 60(2): 403-411, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35348408
2.
Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.
Pulm Pharmacol Ther
; 49: 11-19, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29277690
3.
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.
BMC Pulm Med
; 14: 4, 2014 Jan 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-24438744
4.
Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses.
Pulm Ther
; 9(3): 395-409, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37526856
5.
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
J Asthma Allergy
; 16: 123-134, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36714049
6.
Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study.
Clin Drug Investig
; 43(9): 719-728, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37682405
7.
Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Respir Med
; 211: 107172, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36906187
8.
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Adv Ther
; 39(6): 2365-2378, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35072888
9.
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
BMJ Open Respir Res
; 8(1)2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34452934
10.
Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
Respir Med
; 180: 106311, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33711782
11.
Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
Respir Med
; 161: 105809, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32056721
12.
Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
Lancet Respir Med
; 8(10): 987-999, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32653075
13.
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Lancet Respir Med
; 8(10): 1000-1012, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32653074
14.
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
Int J Chron Obstruct Pulmon Dis
; 11: 1233-43, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27354782
15.
Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Respir Med
; 115: 39-45, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27215502
16.
Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study.
Chronic Obstr Pulm Dis
; 3(2): 549-559, 2016 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28848879
17.
Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.
Int J Chron Obstruct Pulmon Dis
; 10: 1599-612, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26316734
18.
Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
Int J Chron Obstruct Pulmon Dis
; 10: 57-68, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25609940
19.
Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Respir Med
; 108(4): 584-92, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24534204
20.
Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
Curr Med Res Opin
; 30(1): 59-66, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24028677